NEW YORK — DxGen and Precision Diabetes announced on Tuesday an agreement to launch DxGen’s point-of-care analyzer for diabetes-related assays in the US.
The Epithod AutoDx analyzer’s test menu includes assays for hemoglobin A1C, C-reactive protein, and urinary albumin assays, with additional diabetes assays soon to come, the company said. The compact analyzer is suited for use in physician offices, small laboratories, outpatient clinics, and hospitals.
DxGen is a Seoul, South Korea-based developer of point-of-care diagnostics, particularly assays related to diabetes and tuberculosis. Eric Button, founder and CEO of Raleigh, North Carolina-based Precision Diabetes, said that adding the Epithod AutoDx to Precision Diabetes’ portfolio will help his company expand access to clinical diagnostics for early detection, prevention, and management of diabetes, prediabetes, and associated complications.